**Table 3: PICO Framework**

| **PICO Element** | **Inclusion Criteria** | **Exclusion criteria** |
| --- | --- | --- |
| Participants or population | Adults with depression, MDD, or TRD | Under 18 years or any diagnosis other than depression. |
| Intervention or exposure | Psilocybin treatment or antidepressants | - |
| Comparators or Control (where relevant) | Healthy participants or control conditions will include patients without depression who receive a placebo in the clinical process and comparison with other drugs, such as Ketamine, Niacin, or Mirtazapine. | - |
| Outcomes | Measures of emotional state (i.e., biological and subjective).  Measures of neural activity (i.e., results from EEG, fMRI, or other methods). Measures of subjective interpretation (i.e., preference and familiarity). | - |
| Study design | RTC's | Systematic reviews, meta-analyses, case reports, animal studies, editorials, expert opinions, conference abstracts |

Abbreviations:

**MDD**: Major Depressive Disorder; **PICO**- P- Participants, I- Intervention, C- Comparators or control, O-Outcomes; **TRD**: Treatment Resistant Depression.

**EEG** – *Electroencephalography*; **fMRI** – *Functional Magnetic Resonance Imaging.*